Holen Sie sich die Stockscreener-App
4.98
3.32%
0.16
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Is Design Therapeutics Inc. stock a growth or value playTechnical Setup and Return Forecast Engine - Newser
Published on: 2025-08-13 11:59:52 - 선데이타임즈
How to manage a losing position in Rapport Therapeutics Inc.Strategy Builder for Growth Focused Traders - Newser
Using Bollinger Bands to evaluate Design Therapeutics Inc.Free Real Time Alerts Based on AI Prediction - Newser
Technical analysis overview for Design Therapeutics Inc. stockFree Real Time Stock Movement Analysis - Newser
KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth - simplywall.st
Advanced analytics toolkit walkthrough for Design Therapeutics Inc.Swing Trade Picks with High Potential - Newser
Heatmap analysis for Design Therapeutics Inc. and competitorsFree High Yield Stocks With Buy Confirmation - Newser
What momentum shifts mean for Design Therapeutics Inc.Risk Aware Trading Ideas with Alert Levels - Newser
How sentiment analysis helps forecast Design Therapeutics Inc.Free Low Drawdown Real Time Trading Tips - Newser
Trend analysis for Design Therapeutics Inc. this weekNeural Network Based Equity Prediction System - Newser
Long term hold vs stop loss in Design Therapeutics Inc.Insider Strategy for High Conviction Picks - Newser
How to escape a deep drawdown in Design Therapeutics Inc.Smart Risk Entry Zone Technical Analysis - Newser
What high frequency data says about Design Therapeutics Inc.AI Screener for Daily Stock Forecast - Newser
Is Design Therapeutics Inc. stock ready for a breakoutFree Watchlist for Smart Swing Trading - Newser
Design Therapeutics, Inc. shares rise 10.05% intraday after 4DMT reported positive 60-week results from 4D-150 SPECTRA clinical trial in DME. - AInvest
What makes Design Therapeutics Inc. stock attractive to long term investorsPrice Movement and Market Sentiment Analysis - Newser
What MACD and RSI say about Design Therapeutics Inc.Free Daily Chart Pattern Stock Forecast - Newser
Design Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayReal-Time AI Entry Forecast Generator - Newser
Risk vs reward if holding onto Design Therapeutics Inc.Buy Candidate Summary Based on Fundamentals - Newser
What technical models suggest about Design Therapeutics Inc.’s comebackFree Smart Trend Trading with Weekly Signals - Newser
What makes Design Therapeutics Inc. stock price move sharplyReal Chart Based Opportunity Identification - Newser
News impact scoring models applied to Design Therapeutics Inc.Trade Plan With Low Risk High Return - Newser
Machine Learning Models Forecast Design Therapeutics Inc. UptickEntry Plan for Oversold Reversal Stocks Released - metal.it
Backtesting results for Design Therapeutics Inc. trading strategiesFree AI Screening for Swing Trade Picks - Newser
Using flow based indicators on Design Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Will breakout in Design Therapeutics Inc. lead to full recoveryHistorical Stock Summary and ROI Review - Newser
Has Design Therapeutics Inc. found a price floorFree ROI Boosting Trade Opportunity Calendar - Newser
Can momentum traders help lift Design Therapeutics Inc.Free Weekly Return Pick Forecast Reports - Newser
Design Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold, Reports Q2 Financial Results - AInvest
Design Therapeutics reports Q2 EPS (34c), consensus (33c) - TipRanks
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold - TipRanks
Design Therapeutics Clinical Trial Shows Promising PK Data for Friedreich Ataxia Drug | DSGN Stock News - Stock Titan
Market reaction to Design Therapeutics Inc.’s recent newsPredictive Model for Intraday Swing Forecast - Newser
Design Therapeutics, Inc. shares rise 1.26% intraday as Cartesian Therapeutics reports strong clinical trial progress and global expansion. - AInvest
Can Conifer Holdings Inc. hit a new high this monthFree Fast Exit and Entry Strategy Guide - Newser
Fuchs Dystrophy Pipeline 2025: In-depth Clinical Trials - openPR.com
0.91%
3.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):